Anti‐PCSK 9 antibodies increase the ratios of the brain‐specific oxysterol 24S‐hydroxycholesterol to cholesterol and to 27‐hydroxycholesterol in the serum-Reference-Cited by-同舟云学术

Anti‐PCSK 9 antibodies increase the ratios of the brain‐specific oxysterol 24S‐hydroxycholesterol to cholesterol and to 27‐hydroxycholesterol in the serum

Published:2021-05-04 Issue:11 Volume:87 Page:4252-4261
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Lütjohann Dieter¹^ORCID,Stellaard Frans¹,Bölükbasi Bediha²,Kerksiek Anja¹,Parhofer Klaus G.³,Laufs Ulrich²⁴

Affiliation:

1. Institut für Klinische Chemie und Klinische Pharmakologie Universitätsklinikum Bonn Bonn Germany

2. Klinik für Innere Medizin III (Kardiologie, Angiologie und Internistische Intensivmedizin) Universitätsklinikum des Saarlandes Homburg Germany

3. Medizinische Klinik IV—Campus Großhadern Klinikum der Universität München Munich Germany

4. Klinik und Poliklinik für Kardiologie Universitätsklinikum Leipzig Leipzig Germany

Funder

Rheinische Friedrich-Wilhelms-Universität Bonn

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14841

Reference51 articles.

1. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene Is a Risk Factor of Large-Vessel Atherosclerosis Stroke

2. The biochemical and genetic diagnosis of lipid disorders

3. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)

4. New Pharmacological Approaches to Target PCSK9

5. Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association;Arteriosclerosis, Thrombosis, and Vascular Biology;2023-10

2. Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review;Frontiers in Cardiovascular Medicine;2023-06-12